Post-COVID-19 Vaccine Parosmia: A Case Report

We present the case of a healthy 38-year-old male who developed parosmia following a second dose of AstraZeneca with a negative nasal swab of coronavirus disease 2019 (COVID-19) infection. The patient noted parosmia that started suddenly after one week of receiving the second dose of AstraZeneca wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zamzami, Osama S, Kabli, Abdulrahman F, Alhothali, Ammar S, Alhothali, Omar S, Alharbi, Tayil A, Bahakim, Abdullah K, Marglani, Osama A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747983/
https://www.ncbi.nlm.nih.gov/pubmed/35028203
http://dx.doi.org/10.7759/cureus.20292
Descripción
Sumario:We present the case of a healthy 38-year-old male who developed parosmia following a second dose of AstraZeneca with a negative nasal swab of coronavirus disease 2019 (COVID-19) infection. The patient noted parosmia that started suddenly after one week of receiving the second dose of AstraZeneca with no association with other symptoms. The patient has still not recovered from his parosmia until the publication of this article. The olfactory disorder was confirmed using a validated questionnaire for parosmia assessment and examination by rhinoscopy. Parosmia is a rare side effect of COVID-19, and its pathophysiological mechanism is still unknown. More research in the future is needed to know the association of parosmia with COVID-19 vaccine.

Ejemplares similares